Prostaglandin E2 (PGE2) is well known to promote tumor progression by boosting cancer cell proliferation while inhibiting anticancer immunity. Recent data from Lacher et al. and Morotti et al. demonstrate that one of the mechanisms through which PGE2 suppresses tumor-targeting immune responses involves downregulation of interleukin 2 (IL2) receptors and consequent inhibition of mitochondrial metabolism in T cells.
Keywords: CASP3; NK cells; PTGER2; apoptosis; radiation therapy; tumor-infiltrating lymphocyte.
Copyright © 2024 Elsevier Inc. All rights reserved.